TY - JOUR T1 - Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 248 LP - 252 DO - 10.1111/j.1525-1438.1991.tb00050.x VL - 1 IS - 6 AU - J. B. VERMORKEN AU - F. LANDONI AU - S. PECORELLI AU - M. J. PICCART AU - M. E. L. VAN DER BURG AU - W. W. TEN BOKKEL HUININK AU - M. GEORGE AU - S. GREGGI AU - N. ROTMENSZ Y1 - 1991/10/01 UR - http://ijgc.bmj.com/content/1/6/248.abstract N2 - Twenty-nine patients with disseminated squamous cell carcinoma of the uterine cervix were treated with a 3 mg/m2 weekly i.v. bolus schedule of vindesine for 6 weeks (thereafter every 2 weeks). Twenty-seven patients were evaluable for response, 19 of whom had received prior chemotherapy (14 also vincristine). Five of the 27 patients (19%) showed a partial response, all being part of the 22 patients with only distant metastases. No objective response were observed among five patients who also had loco-regional recurrent disease. The median duration of response was 21 (11–58) weeks. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. Vindesine warrants further study in combination chemotherapy protocols for cervical cancer. ER -